Objective:To evaluate the impact of atorvastatin and rosuvastatin at different doses on liver function in the patients with coronary artery disease. Methods:A retrospective study was used, and the patients with coronary heart disease hospitalized in the first hospital of China medical university from January 2013 to March 2014 were selected. According to the drug variety and dosage, the patients were divided into four groups: A (atorvastatin, 20 mg·d-1), B (atorvastatin, 40 mg·d-1), C (rosuvastatin, 10 mg· d-1 ) and D ( rosuvastatin, 20 mg·d-1 ) . The basic information of patients, the indices of liver function( ALT,AST,ALP and TBIL) , the time of abnormal liver function, treatment strategies and prognosis were recorded. The incidence of abnormal liver function in the groups was compared, and the rationality and effectiveness of the intervetion strategies were evaluated. Results:A total of 269 patients were collected. Among them, 149 cases were with abnormal liver function in varying degrees, and 21 patients were with ALT>3?ULN. The incidence of ALT>3?ULN in atorvastatin high dose group was much higher than that in atorvastatin low dose group( P<0. 05). Conclusion:The patients treated with high dose atorvastatin (40 mg·d-1) have a high risk of liver injury.